DiObex

About:

DiObex develops novel products for the treatment of metabolic disorders.

Top Investors: Sofinnova Investments, Domain Associates, Mitsui Global Investment, Inventages Venture Capital Investment Inc., Pequot Capital

Description:

DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

Total Funding Amount:

$31.1M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2003-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2007-04-16

IPO Status:

Private

Industries: